Fragile X Syndrome Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Fragile X Syndrome remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 35 matched trial records and 37 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07654114 | CTH-120 | Phase 2; Recruiting | Connecta Therapeutics SL | Spain | Treatment-emergent adverse events (TEAEs). (From Day 1 to End-of-study: EOS will be on Day 56 (±2 days).); Treatment-emergent potentially clinically significant abnormalities (PSCAs) in blood pressure (mmHg). (From Day 1 to End-of-study (EOS): on Day 56 (±2 days).) | 2027-05-01 |
| NCT07493096 | Intervention not normalized | Not Applicable; Recruiting | Sponsor not listed | United States | Change in Clinician Assessed Functional Neurodevelopmental Performance (Baseline to end of 2 week intensive program) | 2028-01-01 |
| NCT07439510 | SPG-601 | Phase 2/3; Not yet recruiting | Spinogenix, Inc. | Geography not listed | Phase 2b: Change from baseline in Total Cognition Composite Change Sensitive Score from the NIH-TCB (8 weeks); Phase 2b: Change from baseline in EEG resting state relative power bands during rest (8 weeks) | 2030-02-01 |
| NCT07434037 | Intervention not normalized | Not Applicable; Not yet recruiting | Hospices Civils de Lyon | France | Error rate (percentage) for each of the four paradigms. (Day 1); Response time (millisecond) for two of the four paradigms. (Day 1) | 2029-02-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 2a, Randomized, Double-Blinded, Study Evaluating the Neurophysiologic vs Clinical Effects of Single-Dose SPG601 and Placebo in Adult Men With Fragile X Syndrome (Phase 2): the indexed record reports -; Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician(Mean) = 3.7 score on a scale (95% Confidence Interval, 3.106 - 4.07); Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician(Mean) = 3.8 score on a scale (95% Confidence Interval, 3.399 - 4.26).
- Effects of Metformin on children with Fragile X Syndrome: a randomized, double-blind, placebo-controlled trial (Phase 2): the indexed record reports Total ABC score = -4.0 Point ( 23.67); Total ABC score = -16.6 Point ( 15.31).
- Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study (Phase 2): the indexed record reports TRAE = 12.9 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including CTH-120 (Phase 2; TrkB), SPG-601 (Phase 2/3; BK channel). Company & Deal Intelligence records identify sponsor context for Connecta Therapeutics SL, Spinogenix, Inc., Hospices Civils de Lyon. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Fragile X Syndrome has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
